Home › Sistema immunitario e disturbi › Massachusetts › Boston
Studi clinici su Sistema immunitario e disturbi a Boston, MA
10 studi su Sistema immunitario e disturbi cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Massachusetts General Hospital, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
In reclutamentoStudio osservazionale
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
In reclutamentoFase 2
- Dana-Farber Cancer Institute, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Massachusetts General Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
In reclutamentoFase 1/2
- Brigham and Women's Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
In reclutamentoFase 2
- Dana-Farber Cancer Institute, Boston
Studi su Sistema immunitario e disturbi in altre città
- Washington, DC13 studi
- New York City, NY12 studi
- Philadelphia, PA10 studi
- Atlanta, GA9 studi
- Portland, OR9 studi
- Houston, TX9 studi
- Cleveland, OH8 studi
- Chicago, IL8 studi
- Los Angeles, CA8 studi
- Milwaukee, WI6 studi
- Seattle, WA6 studi
- Cedar Rapids, IA6 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.